Clinical Trial Detail

NCT ID NCT02639026
Title Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

pancreatic adenocarcinoma

breast cancer

lung non-small cell carcinoma

melanoma

Therapies

Durvalumab + Tremelimumab

Age Groups: adult

No variant requirements are available.